CNSP — CNS Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1729427 ·
Last close
$4.93
Market Cap
$7.21M
52W High
$10.59
52W Low
$1.90
ADV30
6,910
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,700,000 | -2,588,000 | 21,938,000 | 19,985,000 | 3,738,000 |
| Mar 2026 | 0 | — | -4,975,205 | -4,937,046 | 4,653,192 | 2,950,877 | 4,582,487 |
| Dec 2025 | 0 | — | -5,986,126 | -5,955,802 | 8,623,466 | 7,201,014 | 4,100,910 |
| Sep 2025 | 0 | — | -3,253,388 | -3,218,481 | 11,869,258 | 9,864,087 | 1,959,117 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,217,818
Investing CF
$-10,367
Financing CF
$5,145,457
CapEx
$-6,179
Dividends Paid
—
Buybacks
$-1,486
EPS Diluted TTM
$-38.41
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-105,212,314
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-16,471,157
Pretax Income TTM
$-16,486,290
Interest Exp TTM
$15,133
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,986,559 | -15,850,564 | 8,623,466 | 4,100,910 | 4,522,556 | -13,811,107 |
| Dec 2024 | 0 | -14,901,943 | -14,857,801 | 8,700,943 | 2,524,332 | 6,176,611 | -17,113,299 |
| Dec 2023 | 0 | -18,865,108 | -18,851,226 | 1,700,853 | 6,132,968 | -4,432,115 | -14,140,031 |
| Dec 2022 | 0 | -15,267,107 | -15,274,134 | 13,053,115 | 4,920,259 | 8,132,856 | -10,557,815 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INNPF | INNOCAN PHARMA Corp | $7.29M | $1.62 | — |
| SKYE | Skye Bioscience, Inc. | $7.39M | $1.67 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.43M | $4.74 | — |
| LEXX | Lexaria Bioscience Corp. | $6.91M | $3.28 | — |
| BOLT | Bolt Biotherapeutics, Inc. | $6.90M | $3.58 | — |
News headlines (Yahoo Finance, 1h cache)
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
2026-08-12 12:00 · Yahoo
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
2026-06-08 13:15 · Yahoo
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
2026-05-20 13:02 · Yahoo
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
2026-05-14 15:39 · Yahoo
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
2026-05-14 12:00 · Yahoo
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
2026-05-04 11:00 · Yahoo
CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth
2026-09-01 13:01 · Yahoo
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference
2026-08-27 13:01 · Yahoo
Top Midday Gainers
2026-05-04 17:59 · Yahoo
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
2026-03-11 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.